There is still no study investigating the prognostic performance of CD14⁺⁺CD16⁻, CD14⁺⁺CD16⁺ and CD14⁺CD16⁺⁺ monocyte subpopulations in complicated intra-abdominal infections (cIAIs); therefore, we aimed to evaluate the association between monocyte subtypes and outcome in such patients. A single-center prospective study was conducted at a University Hospital Stara Zagora between November 2018 and August 2021. Preoperatively and on the 3rd postoperative day (POD), we measured the levels of CD14⁺⁺CD16⁻, CD14⁺⁺CD16⁺ and CD14⁺CD16⁺⁺ monocytes in peripheral blood using flow cytometry in 62 patients with cIAIs and 31 healthy controls. Nine of the 62 patients died during hospitalization. Survivors had higher pre-surgery percentages of CD14⁺⁺CD16⁻ classical monocytes and higher percentage of these cells predicted favorable outcome in ROC analysis (AUROC = 0.781, p = 0.008). The CD14⁺⁺CD16⁺ intermediate monocyte percentages were higher in non-survivors both pre- and postoperatively but only the higher preoperative values predicted a lethal outcome (AUROC = 0.722, p = 0.035). For CD14⁺CD16⁺⁺ non-classical monocytes, non-survivors had lower percentages on day 3 post-surgery and low percentage was predictive of lethal outcome (AUROC = 0.752, p = 0.046). Perioperative levels of monocyte subpopulations in peripheral blood show a great potential for prognostication of outcome in patients with cIAIs.

目前尚无研究调查 CD14 ⁺⁺ CD16- ^、 CD14 ⁺⁺ CD16 ⁺和 CD14 ⁺ CD16 ⁺⁺单核细胞亚群在复杂腹腔内感染 (cIAI) 中的预后表现；因此，我们的目的是评估单核细胞亚型与此类患者的预后之间的关联。^{2018 年 11 月至 2021 年 8 月在 Stara Zagora 大学医院进行了一项单中心前瞻性研究。术前和术后第 3 天（POD），我们测量了 CD14 ++} CD16 ⁻、CD14 ⁺⁺ CD16 ⁺和 CD14的水平⁺使用流式细胞术检测 62 名 cIAI 患者和 31 名健康对照者外周血中的CD16 ^{++单核细胞。}62名患者中有9人在住院期间死亡。幸存者的术前 CD14 ⁺⁺ CD16-经典单核细胞百分比较高，并且这些细胞的百分比较高，在 ROC 分析中预测有利结果（AUROC = 0.781，^p =  0.008）。非幸存者术前和术后的CD14 ⁺⁺ CD16 ⁺中间单核细胞百分比均较高，但只有较高的术前值才能预测致命结果（AUROC = 0.722，p  = 0.035）。对于 CD14 ⁺ CD16 ⁺⁺非经典单核细胞，非幸存者在术后第 3 天的百分比较低，并且较低的百分比可以预测致命结果（AUROC = 0.752，p  = 0.046）。外周血中单核细胞亚群的围手术期水平对于预测 cIAI 患者的预后具有巨大潜力。